stockrowOruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
- EPS
- −19.6%
- Free cash flow
- −43.0%
Quarter to June 2026, against a year earlier
Follow ORKA
Alert me
Oruka Therapeutics, Inc. (ORKA) EPS (diluted)
Oruka Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$1.85, compared with −$3.87 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$2.12. Over the past ten years it has ranged from −$392.96 (fiscal 2015) to −$1.85 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 10 consecutive fiscal years. Oruka Therapeutics, Inc. ranks 327th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.85 | — |
| FY2024 | −$3.87 | — |
| FY2023 | −$4.44 | — |
| FY2022 | −$8.28 | — |
| FY2021 | −$16.69 | — |
| FY2020 | −$24.85 | — |
| FY2019 | −$49.82 | — |
| FY2018 | −$123.07 | — |
| FY2017 | −$382.17 | — |
| FY2016 | −$390.80 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.55 | — |
| Mar 2026 | −$0.48 | — |
| Dec 2025 | −$0.54 | — |
| Sep 2025 | −$0.55 | — |
| 41 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $2.24 |
| ORKA Oruka Therapeutics, Inc. | −$2.12 |
| CGON CG Oncology, Inc. compare | −$2.69 |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$2.73 |
| IMVT Immunovant, Inc. compare | −$2.82 |
| AXSM Axsome Therapeutics, Inc. compare | −$3.06 |
| IONS Ionis Pharmaceuticals, Inc. compare | −$3.46 |
| KOD Kodiak Sciences Inc. compare | −$4.19 |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$15.22 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item